Indications -- scarring, fibrosis, adhesions, keloids Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- scarring, fibrosis, adhesions, keloids

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (15)	4/12/2006 8:56:41 AM
From: nigel bates	Read Replies (1) of 32

Best pure play in the indication is now public. 12 April, 2006 - Renovo Group plc, the biopharmaceutical product company developing a portfolio of drugs to prevent and reduce scarring in the skin and other external and internal parts of the body, is pleased to announce that its ordinary shares have been admitted to the Official List of the Financial Services Authority and to trading on London Stock Exchange's main market for listed securities (ticker symbol RNVO). Unconditional dealings in Renovo's ordinary shares commenced at 8.00am today... IPO'd at 87p - trading around £1.12 currently. 177,170,297 shares in issue, free float 37% of that (subject to overallotments ?).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next